{
    "Trade/Device Name(s)": [
        "SeraQuest HSV Type 2 Specific IgG",
        "SeraQuest\u00ae HSV Type 2 Specific IgG"
    ],
    "Submitter Information": "Quest International, Inc.",
    "510(k) Number": "K152353",
    "Predicate Device Reference 510(k) Number(s)": [],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "MYF"
    ],
    "Summary Letter Date": "April 14, 2016",
    "Summary Letter Received Date": "April 14, 2016",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 866.3305"
    ],
    "Regulation Name(s)": [
        "Herpes simplex virus serological assays"
    ],
    "Analyte Class(es)": [
        "immunology",
        "virology",
        "serology"
    ],
    "Analyte(s)": [
        "HSV-2 IgG antibodies"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Enzyme-linked immunosorbent assay (ELISA)",
        "Enzyme immunoassay"
    ],
    "Methodologies": [
        "Solid-phase ELISA"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Calibrator",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for SeraQuest HSV Type 2 Specific IgG ELISA assay for qualitative detection of human IgG antibodies to HSV-2 in serum.",
    "Indications for Use Summary": "Intended for in vitro qualitative detection of human IgG antibodies to HSV-2 in serum from sexually active individuals and expectant mothers as an aid in presumptive diagnosis of HSV-2 infection; not cleared for donor screening, immunocompromised or pediatric patients, or non-serum matrices.",
    "fda_folder": "Microbiology"
}